mk-0686
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2004 (NCT00533403)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Bradykinin B1 receptorANTAGONIST
BDKRB1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)c1c(Cl)cccc1-c1ccc([C@@H](C)NC(=O)C2(NC(=O)C(F)(F)F)CC2)c(F)c1- Mol. weight
- 486.85 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL232943 ↗
Also known as
- methyl 3-chloro-3'-fluoro-4'-(1-(((1-((trifluoroacetyl)amino)cyclopropyl)carbonyl)amino)ethyl)-1,1'-biphenyl-2-carboxylate
- methyl cftbc
- mk0686
- mk0686
- mk0686
- mk0686
- mk 0686
- mk-0686
- mk-0686
- mk-0686
- mk-0686
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00282763 | Phase 2 | Dec 1, 2005 | Merck |
| NCT00296569 | Phase 2 | Sep 1, 2005 | Merck |
| NCT00533403 | Phase 2 | Jul 1, 2004 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 1 | 2004 |
1 organizations
Page 1 / 1